Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 919 | 175 | 729 |
| Samples | 513 | 111 | 398 |
| Peptides | 423 | 78 | 345 |
Function
PPP2R3A · Protein phosphatase 2 regulatory subunit B''alpha
This gene encodes one of the regulatory subunits of the protein phosphatase 2. Protein phosphatase 2 (formerly named type 2A) is one of the four major Ser/Thr phosphatases and is implicated in the negative control of cell growth and division. Protein phosphatase 2 holoenzymes are heterotrimeric proteins composed of a structural subunit A, a catalytic subunit C, and a regulatory subunit B. The regulatory subunit is encoded by a diverse set of genes that have been grouped into the B/PR55, B'/PR61, and B''/PR72 families. These different regulatory subunits confer distinct enzymatic specificities and intracellular localizations to the holozenzyme. The product of this gene belongs to the B'' family. The B'' family has been further divided into subfamilies. The product of this gene belongs to the alpha subfamily of regulatory subunit B''. Alternative splicing results in multiple transcript variants encoding different isoforms.[provided by RefSeq, Jun 2010].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 404 amino-acid changes on canonical ENST00000264977 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PPP2R3A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PPP2R3A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Endometrial Carcinoma | 7/42 17% | 22/612 4% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Melanoma | 13/210 6% | 58/1899 3% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Bladder Carcinoma | 4/58 7% | 21/956 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Colorectal Carcinoma | 12/143 8% | 54/3239 2% |
| Non-Small Cell Lung Carcinoma | 12/304 4% | 18/1390 1% |
| Other Solid Cancers | 3/94 3% | 23/1515 2% |
| Gastric Carcinoma | 1/74 1% | 26/1809 1% |
| Mesothelioma | 2/62 3% | 1/165 1% |
| Cervical Carcinoma | 1/35 3% | 5/422 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 11/810 1% |
| Non-Cancerous | 3/104 3% | 7/830 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 24/2550 1% |
| Thyroid Gland Carcinoma | 4/45 9% | 11/1592 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Biliary Tract Carcinoma | 4/54 7% | 5/950 1% |
| Plasma Cell Myeloma | 3/44 7% | 0/305 0% |
| Neuroendocrine Tumour | 3/154 2% | 3/577 1% |
| Pancreatic Carcinoma | 3/89 3% | 10/1611 1% |
| Glioma | 0/52 0% | 16/2127 1% |
| Ovarian Carcinoma | 4/109 4% | 4/998 0% |
| Head and Neck Carcinoma | 0/85 0% | 11/1574 1% |
| Esophageal Carcinoma | 0/23 0% | 5/769 1% |
| Ewings Sarcoma | 1/63 2% | 1/262 0% |
Mutation Distribution
Where PPP2R3A is mutated · all tissues, split by cell line vs tissue
How many mutations in PPP2R3A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 919 mutations in PPP2R3A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|